Publications by authors named "J C Bolanos Ancona"
Independent evolutionary lineages or species that lack phenotypic variation as an operative criterion for their delimitation are known as cryptic species. However, these have been delimited using other data sources and analysis. The aims of this study are: (1) to evaluate the divergence of the populations of the complex; and (2) to delimit the species using multilocus data, phylogenetic analysis and the coalescent model.
View Article and Find Full Text PDFPurpose: Evidence supports treatment for opioid use disorder (OUD) with buprenorphine in primary care practices (PCPs). Barriers that slow implementation of this treatment include inadequately trained staff. This study aimed to increase the number of rural PCPs providing OUD treatment with buprenorphine.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on understanding community perspectives regarding medication-assisted treatment (MAT) for opioid use disorder (OUD) as a means to change the conversation around this public health issue.
- Community members collaborated with researchers to develop interventions aimed at increasing awareness and promoting positive attitudes toward MAT in rural Colorado.
- Findings showed that greater exposure to these local intervention materials correlated with improved knowledge and beliefs about OUD, suggesting that community-driven strategies are effective in addressing the opioid crisis.
Background And Objective: Central venous catheters in the NICU are associated with significant morbidity and mortality because of the risk of central line-associated bloodstream infections (CLABSIs). The purpose of this study was to determine the effect of catheter dwell time on risk of CLABSI.
Methods: Retrospective cohort study of 13,327 infants with 15,567 catheters (93% peripherally inserted central catheters [PICCs], 7% tunneled catheters) and 256,088 catheter days cared for in 141 NICUs.
Background: Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type virus (95% inhibitory concentration 19 nM, 50% human serum). Doravirine has low potential to cause drug-drug interactions since it is primarily eliminated by oxidative metabolism and does not inhibit or significantly induce drug-metabolizing enzymes.
Methods: The pharmacokinetics and safety of doravirine were investigated in two double-blind, dose-escalation studies in healthy males.